Literature DB >> 27849586

Origins of the current seventh cholera pandemic.

Dalong Hu1,2, Bin Liu1,3, Lu Feng1,2,4, Peng Ding1, Xi Guo1, Min Wang1, Boyang Cao1,2,4, Peter R Reeves5, Lei Wang6,2,4,7.   

Abstract

Vibrio cholerae has caused seven cholera pandemics since 1817, imposing terror on much of the world, but bacterial strains are currently only available for the sixth and seventh pandemics. The El Tor biotype seventh pandemic began in 1961 in Indonesia, but did not originate directly from the classical biotype sixth-pandemic strain. Previous studies focused mainly on the spread of the seventh pandemic after 1970. Here, we analyze in unprecedented detail the origin, evolution, and transition to pandemicity of the seventh-pandemic strain. We used high-resolution comparative genomic analysis of strains collected from 1930 to 1964, covering the evolution from the first available El Tor biotype strain to the start of the seventh pandemic. We define six stages leading to the pandemic strain and reveal all key events. The seventh pandemic originated from a nonpathogenic strain in the Middle East, first observed in 1897. It subsequently underwent explosive diversification, including the spawning of the pandemic lineage. This rapid diversification suggests that, when first observed, the strain had only recently arrived in the Middle East, possibly from the Asian homeland of cholera. The lineage migrated to Makassar, Indonesia, where it gained the important virulence-associated elements Vibrio seventh pandemic island I (VSP-I), VSP-II, and El Tor type cholera toxin prophage by 1954, and it then became pandemic in 1961 after only 12 additional mutations. Our data indicate that specific niches in the Middle East and Makassar were important in generating the pandemic strain by providing gene sources and the driving forces for genetic events.

Entities:  

Keywords:  Vibrio cholerae; comparative genomics; evolution; pandemic

Mesh:

Year:  2016        PMID: 27849586      PMCID: PMC5137724          DOI: 10.1073/pnas.1608732113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models.

Authors:  Alexandros Stamatakis
Journal:  Bioinformatics       Date:  2006-08-23       Impact factor: 6.937

2.  Public Health Weekly Reports for MARCH 15, 1912.

Authors: 
Journal:  Public Health Rep       Date:  1912-03-15       Impact factor: 2.792

3.  Humoral Immunity in the Gut Selectively Targets Phenotypically Virulent Attaching-and-Effacing Bacteria for Intraluminal Elimination.

Authors:  Nobuhiko Kamada; Kei Sakamoto; Sang-Uk Seo; Melody Y Zeng; Yun-Gi Kim; Marilia Cascalho; Bruce A Vallance; José L Puente; Gabriel Núñez
Journal:  Cell Host Microbe       Date:  2015-04-30       Impact factor: 21.023

4.  Phenotypic, genotypic, and antibiotic sensitivity patterns of strains isolated from the cholera epidemic in Zimbabwe.

Authors:  Mohammad S Islam; Zahid H Mahmud; Mohammad Ansaruzzaman; Shah M Faruque; Kaisar A Talukder; Firdausi Qadri; Munirul Alam; Shafiqul Islam; Pradip K Bardhan; Ramendra N Mazumder; Azharul I Khan; Sirajuddin Ahmed; Anwarul Iqbal; Owen Chitsatso; James Mudzori; Sheetal Patel; Stanley M Midzi; Lincoln Charimari; Hubert P Endtz; Alejandro Cravioto
Journal:  J Clin Microbiol       Date:  2011-04-06       Impact factor: 5.948

5.  Second-pandemic strain of Vibrio cholerae from the Philadelphia cholera outbreak of 1849.

Authors:  Alison M Devault; G Brian Golding; Nicholas Waglechner; Jacob M Enk; Melanie Kuch; Joseph H Tien; Mang Shi; David N Fisman; Anna N Dhody; Stephen Forrest; Kirsten I Bos; David J D Earn; Edward C Holmes; Hendrik N Poinar
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

6.  Hyperinfectivity of human-passaged Vibrio cholerae can be modeled by growth in the infant mouse.

Authors:  Ashfaqul Alam; Regina C Larocque; Jason B Harris; Cecily Vanderspurt; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Chitin induces natural competence in Vibrio cholerae.

Authors:  Karin L Meibom; Melanie Blokesch; Nadia A Dolganov; Cheng-Yen Wu; Gary K Schoolnik
Journal:  Science       Date:  2005-12-16       Impact factor: 47.728

Review 8.  Whole-genome sequence comparisons reveal the evolution of Vibrio cholerae O1.

Authors:  Eun Jin Kim; Chan Hee Lee; G Balakrish Nair; Dong Wook Kim
Journal:  Trends Microbiol       Date:  2015-04-24       Impact factor: 17.079

9.  Vibrio cholerae O1 isolate with novel genetic background, Thailand-Myanmar.

Authors:  Kazuhisa Okada; Amonrattana Roobthaisong; Witaya Swaddiwudhipong; Shigeyuki Hamada; Siriporn Chantaroj
Journal:  Emerg Infect Dis       Date:  2013-06       Impact factor: 6.883

10.  Population structure and evolution of non-O1/non-O139 Vibrio cholerae by multilocus sequence typing.

Authors:  Sophie Octavia; Anna Salim; Jacob Kurniawan; Connie Lam; Queenie Leung; Sunjukta Ahsan; Peter R Reeves; G Balakrish Nair; Ruiting Lan
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more
  50 in total

1.  Reviving Phage Therapy for the Treatment of Cholera.

Authors:  Sudhakar Bhandare; Joan Colom; Abiyad Baig; Jenny M Ritchie; Habib Bukhari; Muhammad A Shah; Banwarilal L Sarkar; Jingliang Su; Brendan Wren; Paul Barrow; Robert J Atterbury
Journal:  J Infect Dis       Date:  2019-02-15       Impact factor: 5.226

2.  Two defence systems eliminate plasmids from seventh pandemic Vibrio cholerae.

Authors:  Milena Jaskólska; David W Adams; Melanie Blokesch
Journal:  Nature       Date:  2022-04-06       Impact factor: 49.962

3.  Phage defence by deaminase-mediated depletion of deoxynucleotides in bacteria.

Authors:  Brian Y Hsueh; Geoffrey B Severin; Clinton A Elg; Evan J Waldron; Abhiruchi Kant; Alex J Wessel; John A Dover; Christopher R Rhoades; Benjamin J Ridenhour; Kristin N Parent; Matthew B Neiditch; Janani Ravi; Eva M Top; Christopher M Waters
Journal:  Nat Microbiol       Date:  2022-07-11       Impact factor: 30.964

4.  Sequence Polymorphisms in Vibrio cholerae HapR Affect Biofilm Formation under Aerobic and Anaerobic Conditions.

Authors:  Jant Cres Caigoy; Toshi Shimamoto; Asish Kumar Mukhopadhyay; Sumio Shinoda; Tadashi Shimamoto
Journal:  Appl Environ Microbiol       Date:  2022-08-15       Impact factor: 5.005

5.  A Vibrio cholerae Core Genome Multilocus Sequence Typing Scheme To Facilitate the Epidemiological Study of Cholera.

Authors:  Kevin Y H Liang; Fabini D Orata; Mohammad Tarequl Islam; Tania Nasreen; Munirul Alam; Cheryl L Tarr; Yann F Boucher
Journal:  J Bacteriol       Date:  2020-11-19       Impact factor: 3.490

Review 6.  Vaccine development for emerging infectious diseases.

Authors:  Jean-Louis Excler; Melanie Saville; Seth Berkley; Jerome H Kim
Journal:  Nat Med       Date:  2021-04-12       Impact factor: 53.440

Review 7.  The ever-expanding world of bacterial cyclic oligonucleotide second messengers.

Authors:  Soo Hun Yoon; Christopher M Waters
Journal:  Curr Opin Microbiol       Date:  2021-02-25       Impact factor: 7.584

8.  Antimicrobial Activity of the Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG) against Clinical Isolates of Multidrug-Resistant Vibrio cholerae.

Authors:  Achiraya Siriphap; Anong Kiddee; Acharaporn Duangjai; Atchariya Yosboonruang; Grissana Pook-In; Surasak Saokaew; Orasa Sutheinkul; Anchalee Rawangkan
Journal:  Antibiotics (Basel)       Date:  2022-04-13

9.  Recent Vibrio cholerae O1 Epidemic Strains Are Unable To Replicate CTXΦ Prophage Genome.

Authors:  Kaoru Ochi; Tamaki Mizuno; Prosenjit Samanta; Asish K Mukhopadhyay; Shin-Ichi Miyoshi; Daisuke Imamura
Journal:  mSphere       Date:  2021-06-09       Impact factor: 4.389

10.  Passive Immunity to Vibrio cholerae O1 Afforded by a Human Monoclonal IgA1 Antibody Expressed in Milk.

Authors:  Danielle E Baranova; Lihow Chen; Margaret Destrempes; Harry Meade; Nicholas J Mantis
Journal:  Pathog Immun       Date:  2020-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.